MXCT

Over the past six months, MaxCyte's stock price has fluctuated, decreasing by 26.23% over the last 12 months and by 22.90% year-to-date as of September 18, 2026, and by 5.91% in the past month. Key events included River Global Investors disclosing a 6.1% stake on May 13, 2026, VectorBuilder partnering with MaxCyte on June 22, 2026, and MaxCyte granting Roche a cell therapy technology license on July 20, 2026, which caused its stock to surge due to a Genentech deal. On August 12, 2026, MaxCyte reiterated its 2026 revenue outlook of $30 million to $32 million and reported Q2 2026 earnings per share of -$0.08, beating estimates. News emerged on September 22, 2026, about a new executive with extensive experience, and on October 10, 2026, MaxCyte's stock price traded down 1%.